Clinical trials: Thromboembolic Disease
Intracerebral Haemorrhage (ICH), Cerebral Infarction
The Erlanger Stroke Registry (ESPro) is the Only Ongoing Prospective Population-based Stroke Registry in Germany, Started in 1994. ESPro Includes All Hospitalized and Non-hospitalized Patients With Stroke in the Community of Erlangen (120.000 Inhabitants), With a Long-life Follow-up.
Stroke is a disease that primarily affects older adults and, with an estimated 64,000 deaths in 2024, is one of the leading causes of death in Germany.
- Conditions
- Intracerebral Haemorrhage (ICH), Cerebral Infarction, Cerebral Infarction Due to Thrombosis of Cerebral Arteries, Cerebral Infarction Due to Embolism of Cerebral Arteries
- Trial name
- ESPro (NCT07771335)
- Where
- 3 sites in Germany
- Volunteers
- 17,000 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Venous Thromboembolism
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
Hospital acquired thrombosis describes blood clots that form in the legs and lungs after someone is treated in hospital. Clots in the leg can cause swelling, pain and other problems.
- Trial name
- PETS (NCT05347550)
- Testing
- Graduated Compression Stockings - Thromboembolic deterrent stockings
- Where
- 9 sites in United Kingdom
- Volunteers
- 21,472 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Venous Thromboembolism, Pulmonary Embolism
Venous Thromboembolism in DM1
The risk for venous thromboembolism (VTE) in DM1 and in other inherited myopathies, which can lead to chronic immobilization, are unknown.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Myopathy
- Trial name
- DM1-VTE (NCT03141749)
- Volunteers
- 2,810 people
- Sponsor
- Institut de Myologie, France
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism
Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered
The Brigham and Women's Hospital (BWH) Patient Safety Learning Laboratory (PSLL) focuses on developing health information technology (HIT) tools to engage patients, family, and professional care team members in reliable…
- Conditions
- Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection
- Trial name
- PSLL (NCT02969343)
- Testing
- Patient Safety health information technology
- Where
- United States
- Volunteers
- 21,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer, Thromboembolism
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014352
- Testing
- docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Venous Thromboembolism
Safety and Efficacy Study of Fitaya Vena Cava Filter
A Multi-center, Randomized Controlled Trial to evaluate the safety and efficacy of Fitaya Vena Cava Filter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for deep vein thrombosis.
- Trial name
- NCT03691753
- Testing
- Fitaya Vena Cava Filter System, Aegisy Vena Cava Filter
- Where
- 13 sites in China
- Volunteers
- 186 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Total Knee Replacement Surgeries
Risk Stratification Procedure for Thromboembolism Prophylaxis
The main objective for this study is validation for the proposed risk stratification tool, by evaluating the clinical outcomes for its use post TKR Surgeries. For this objective, the design that is used is Randomized Trial.
- Trial name
- NCT04031859
- Testing
- acetylsalicylic acid
- Where
- Saudi Arabia
- Volunteers
- 242 people
- Sponsor
- Ministry of Health, Saudi Arabia
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Venous Thromboembolic Disease, Pulmonary Embolism
CHIPs-VTE Study in Hospitalized Patients With Lung Cancer
Venous thromboembolism (VTE) is a common complication of malignancies, in particular to lung cancer. Patients with lung cancer in surgical and medical departments are at high risk of VTE development.
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT04158973
- Testing
- Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge, Routine VTE prophylaxis in hospital
- Volunteers
- 3,200 people
- Sponsor
- China-Japan Friendship Hospital
Intracranial Thrombosis
adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
- Trial name
- VECTOR (NCT04139486)
- Testing
- combined EMBOTRAP II or III and Contact Aspiration, Contact Aspiration alone
- Where
- 23 sites in France
- Volunteers
- 526 people
- Sponsor
- Nantes University Hospital
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism, Hemorrhage
A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients
The purpose of this study is to analyze the effect of the prophylaxis of venous thromboembolism in the critical ill patients, and at the same time, to find out the risk of venous thromboembolism and hemorrhage events occurred…
- Trial name
- VTEH (NCT02213978)
- Where
- China
- Volunteers
- 1,114 people
- Sponsor
- Beijing Chao Yang Hospital
Major Non-cardiac Surgeries
A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery
A Phase IV trial of a hospital policy of Tranexamic acid to reduce transfusion in major non-cardiac surgery.
- Trial name
- TRACTION (NCT04803747)
- Testing
- Tranexamic acid (TXA)
- Where
- 10 sites in Canada
- Volunteers
- 8,421 people
- Sponsor
- University of Manitoba
Venous Thromboembolic Disease
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated.
- Trial name
- ENOX-VTD-H (NCT05150314)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Strasbourg, France
Venous Thromboembolism, Deep Vein Thrombosis
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
Blood clots in leg veins (deep vein thrombosis) or lung arteries (pulmonary embolism) that happen for no reason (i.e. unexplained) are both called "unprovoked venous thromboembolism" (VTE).
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- SOME (NCT00773448)
- Testing
- Comprehensive computed tomography of the abdomen/pelvis, Limited Malignancy Screening
- Where
- 9 sites in Canada
- Volunteers
- 862 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thrombosis, Pulmonary Embolism
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against DVT and PE in Patients Undergoing Major Lung Resection
Postoperative venous thromboembolism (VTE) is a significant health-care problem, resulting in significant morbidity, mortality and resource utilization. The true incidence is unknown, and may range from 1% to 15%.
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Lung Neoplasms
- Trial name
- NCT02258958
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Covid19, Venous Thromboembolism
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
- Trial name
- MICHELLE (NCT04662684)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- Science Valley Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.